Literature DB >> 3944353

Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine.

W Kiowski, P Erne, O Bertel, P Bolli, F Bühler.   

Abstract

The importance of counterregulatory mechanisms triggered by arterial vasodilation for the antihypertensive response to the calcium entry blocking agent nifedipine was investigated in 13 men with mild to moderate essential hypertension. Blood pressure and systemic vascular resistance were significantly reduced 30 minutes after sublingual administration of 10 mg of nifedipine while heart rate, cardiac index and plasma norepinephrine concentrations increased (all p less than 0.01). Also, changes in mean blood pressure correlated inversely with arterial baroreflex sensitivity (r = -0.74, p less than 0.01), suggesting that arterial baroreflex mechanisms by means of sympathetic activation tend to limit the acute antihypertensive response. Blood pressure, but not systemic vascular resistance, decreased further (p less than 0.01) after 6 weeks of therapy with nifedipine 20 mg three times daily, while average heart rate, cardiac index and plasma norepinephrine concentrations had returned toward pretreatment values. Thus, a reduction of acutely increased sympathetic activity toward pretreatment values during long-term nifedipine therapy was associated with further decreases in blood pressure. The importance of sympathetic activity was also stressed by the finding of an inverse relation between chronic changes in heart rate and blood pressure (percent of control, r = -0.76, p less than 0.01). Blood volume did not change during long-term nifedipine therapy. The results suggest that the degree of sympathetic reflex activation in part determines the antihypertensive response to nifedipine monotherapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3944353     DOI: 10.1016/s0735-1097(86)80503-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

1.  Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Authors:  Anke-Katrin Volz; Andreas Krause; Walter Emil Haefeli; Jasper Dingemanse; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 2.  Use of nifedipine in hypertension and Raynaud's phenomenon.

Authors:  W Kiowski; P Erne; F R Bühler
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study.

Authors:  K S Woo; C O Pun
Journal:  West J Med       Date:  1990-02

4.  Controversies concerning calcium antagonists.

Authors:  P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 5.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 6.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

7.  Decreased cardiac L-type Ca²⁺ channel activity induces hypertrophy and heart failure in mice.

Authors:  Sanjeewa A Goonasekera; Karin Hammer; Mannix Auger-Messier; Ilona Bodi; Xiongwen Chen; Hongyu Zhang; Steven Reiken; John W Elrod; Robert N Correll; Allen J York; Michelle A Sargent; Franz Hofmann; Sven Moosmang; Andrew R Marks; Steven R Houser; Donald M Bers; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

8.  Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine.

Authors:  M Bellet; P Sassano; T Guyenne; P Corvol; J Menard
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

9.  Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study.

Authors:  F Arzilli; E Gandolfi; C Del Prato; P Innocenti; F Ponzanelli; A Caiazza; F Ghisoni; P Saba; F Giuntoli; C Borgnino
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Haemodynamic effects of a new dihydropyridine calcium entry blocker, S-12968-(-), in a rat model of cardiovascular calcium overload.

Authors:  T Makki; I Lartaud; L Bray-des Boscs; C Capdeville-Atkinson; J M Chillon; M Hoffman; J P Nicolas; J Atkinson
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.